Gilliam Joseph E sells $10.8M of GKOSGilliam Joseph E 内部减持 GKOS $10.8M
Ophthalmic medical technology company Glaukos (ticker: GKOS, $11.2B market cap) President & COO Gilliam Joseph E completed an open-market stock sale on August 11, 2026, selling 60,000 common shares at an average price of $179.74 for total proceeds of $10,784,659. The transaction was disclosed to the U.S. SEC via a Form 4 insider trading filing on August 13, 2026.
Core Transaction Details & Signal Context
The total proceeds of this trade represent 0.097% of GKOS’s current total market capitalization, making it a relatively small single-insider sale. As a core operational leader of the company, Gilliam Joseph E’s open-market sale falls within the routine insider trading reporting scope for executive officers, but his transaction as a key member of management warrants cross-referencing with other public disclosures.
Cross-Reference Signals
Per publicly available SEC filings, Gilliam Joseph E submitted multiple Form 4 filings on August 13, 2026, including two S-Sale open-market trades totaling 60,000 shares with combined proceeds of ~$10,784,659, plus several M-Exempt transactions. Separately, Glaukos reported better-than-expected Q2 2026 earnings on July 29, 2026: actual revenue of $185.61 million, above the consensus estimate of $150.93 million, and adjusted EPS of -$0.14, beating the consensus estimate of -$0.21. As of December 31, 2025, GKOS had 339 institutional holders (up 14 from the prior period), with institutional ownership of 99.8% of the float.
Signal Limitations
This Form 4 filing only discloses the transaction timing, share count, and execution price, and does not specify whether the trade was executed under a pre-arranged 10b5-1 trading plan. As such, the specific motive for the sale (e.g., personal financial planning, liquidity needs) cannot be confirmed, and the trade alone does not reflect on the company’s future business prospects or valuation. Additionally, the small size of this single transaction means it does not represent a broad institutional or executive view of GKOS’s stock.
Follow-up Markers
Investors should monitor subsequent Form 4 filings for Gilliam Joseph E, Glaukos’s Q3 2026 earnings report scheduled for November 4, 2026, and any changes to institutional holdings of GKOS in future 13F filings.
眼科医疗科技公司Glaukos（股票代码GKOS，市值112亿美元）总裁兼首席运营官Gilliam Joseph E于2026年8月11日完成一笔公开市场股票出售，合计抛售60,000股普通股，交易均价179.74美元，总成交额10,784,659美元，该交易于2026年8月13日通过Form 4内幕交易申报文件向美国SEC披露。
核心交易细节与信号背景
该笔交易的总成交额占GKOS当前总市值的0.097%，属于单笔规模较小的高管减持行为。作为公司核心运营负责人，Gilliam Joseph E的公开市场抛售属于内幕交易申报范畴内的常规高管交易，但其作为核心管理层的交易行为仍需结合同期其他披露信息进行交叉验证。
交叉参考信号
根据SEC已披露的文件，Gilliam Joseph E在2026年8月13日当天还提交了多笔Form 4申报，包括两笔公开市场出售（S-Sale类）合计60,000股，总成交额约10,784,659美元，以及多笔M-Exempt豁免交易。此外，GKOS在2026年7月29日发布的2026年第二季度财报超出市场预期：实际营收1.856亿美元，高于市场预期的1.509亿美元，EPS为-0.14美元，优于预期的-0.21美元。截至2025年12月31日，GKOS的机构持股比例达99.8%，共有339家机构持仓，较此前季度增加14家。
信号局限性
本次Form 4申报仅披露了交易的时间、数量和成交价格，未明确该交易是否基于10b5-1预先安排交易计划，因此无法直接推断该减持的具体动机（如个人财务规划、流动性需求等），也无法直接关联公司未来的业务前景或估值变化。此外，该单笔交易的规模较小，不足以代表公司整体管理层对股价的整体判断。
后续关注点
投资者可关注后续Gilliam Joseph E的其他内幕交易申报文件，以及GKOS在2026年11月4日将发布的第三季度财报数据，同时留意机构持仓的后续变动情况。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。